Case Report
J Rheum Dis 2011; 18(2): 118-121
Published online June 30, 2011
© Korean College of Rheumatology
류마티스관절염에 동반된 만성 골수성 백혈병 환자에서 Imatinib Mesylate 효과 보고 1예
전혜경1ㆍ박영은1ㆍ김성일1ㆍ박성후1ㆍ백승훈1ㆍ이정욱1ㆍ하동우1ㆍ이혜원1ㆍ정주섭1ㆍ이승희2ㆍ이은엽2
부산대학교 의학전문대학원 내과학교실1, 진단검사의학교실2
Efficacy of Imatinib Mesylate Treatment for a Patient with Rheumatoid Arthritis and Who Developed Chronic Myelogenous Leukemia
Correspondence to : Young Eun Park
Rheumatoid arthritis is associated with an increased risk of hematological malignancy as a result of the RA itself or its treatment. We report here on an unusual case of a 55-year-old female with long-standing rheumatoid arthritis and who was treated with low dose methotrexate and hydrochloroquine. She was diagnosed with chronic myelogenous leukemia that manifested with severe thrombocytosis and basophilia, and this was treated with imatinib mesylate. After 6 months, she achieved a complete cytogenetic response of the CML and a complete resolution of all the RA symptoms without DMARDs.
Keywords Rheumatoid arthritis, Chronic myelogenous leukemia, Imatinib mesylate
PDF
Standard view
Export citation
Share Article
Case Report
J Rheum Dis 2011; 18(2): 118-121
Published online June 30, 2011
Copyright © Korean College of Rheumatology.
류마티스관절염에 동반된 만성 골수성 백혈병 환자에서 Imatinib Mesylate 효과 보고 1예
전혜경1ㆍ박영은1ㆍ김성일1ㆍ박성후1ㆍ백승훈1ㆍ이정욱1ㆍ하동우1ㆍ이혜원1ㆍ정주섭1ㆍ이승희2ㆍ이은엽2
부산대학교 의학전문대학원 내과학교실1, 진단검사의학교실2
Efficacy of Imatinib Mesylate Treatment for a Patient with Rheumatoid Arthritis and Who Developed Chronic Myelogenous Leukemia
Hye Kyung Jeon1, Young Eun Park1, Sung Il Kim1, Seong Hu Park1, Seung Hoon Baek1, Joung Wook Lee1, Dong Woo Ha1, Hye Won Lee1, Joo Seop Chung1, Seung Hee Lee2, Eun Yup Lee2
Departments of Internal Medicine1, Laboratory Medicine2, Pusan National University School of Medicine, Busan, Korea
Correspondence to:Young Eun Park
Abstract
Rheumatoid arthritis is associated with an increased risk of hematological malignancy as a result of the RA itself or its treatment. We report here on an unusual case of a 55-year-old female with long-standing rheumatoid arthritis and who was treated with low dose methotrexate and hydrochloroquine. She was diagnosed with chronic myelogenous leukemia that manifested with severe thrombocytosis and basophilia, and this was treated with imatinib mesylate. After 6 months, she achieved a complete cytogenetic response of the CML and a complete resolution of all the RA symptoms without DMARDs.
Keywords: Rheumatoid arthritis, Chronic myelogenous leukemia, Imatinib mesylate
Article Tools
Stats or Metrics
Share this article on
Related articles in JRD
-
Risk of acute myocardial infarction associated with anti-rheumatic agents in patients with rheumatoid arthritis: a nationwide population-based case-control study
Soo Min Ahn, M.D., Ph.D., Seonok Kim, MSc., Ye-Jee Kim, Ph.D., Seokchan Hong, M.D., Ph.D., Chang-Keun Lee, M.D., Ph.D., Bin Yoo, M.D., Ph.D., Ji Seon Oh, M.D., Ph.D., Yong-Gil Kim, M.D., Ph.D.
J Rheum Dis -0001; (): -
Evaluation of 14-3-3eta protein as a diagnostic biomarker in the initial assessment of inflammatory arthritis
Roshan Subedi, M.D., Afrah Misbah, M.D., Adnan Al Najada, M.D., Anthony James Ocon, M.D., Ph.D.
J Rheum Dis -0001; (): -
Impact of disease-related indicators on pain measures in rheumatoid arthritis: a biopsychosocial perspective
Hee Jun Kim, R.N., Ph.D., Ju-Yang Jung, M.D., Ph.D., Ji-Won Kim, M.D., Chang-Hee Suh, M.D., Ph.D., Hyoun-Ah Kim, M.D., Ph.D.
J Rheum Dis 2025; 32(1): 38-47
